Trials / Completed
CompletedNCT00097188
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rituximab |
Timeline
- Start date
- 2004-12-01
- Completion
- 2006-12-01
- First posted
- 2004-11-19
- Last updated
- 2014-03-04
Locations
31 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00097188. Inclusion in this directory is not an endorsement.